Pharmaceuticals

As the $525B cold chain market booms and regulations tighten, Circle Logistics is enhancing its services to offer shippers greater reliability and compliance.

A new once-daily pill for hypoparathyroidism begins human testing, promising to replace burdensome injections and transform patient care. Is this the future?

A new alliance aims to deliver nine vital rare disease therapies to Africa, tackling one of global health's most profound access challenges.

ANI Pharmaceuticals launches a generic version of Carbatrol, aiming for a slice of a $65M market and promising improved patient access for chronic conditions.

Orum Therapeutics adds deep clinical and dealmaking expertise to its board, signaling a strategic acceleration of its innovative DAC pipeline for cancer.

Biotech firm Epitopea adds top expert Dr. Lisa Butterfield, validating its novel RNA vaccine approach targeting hidden cancer antigens for hard-to-treat tumors.

Endpoint's new RTSM platform update introduces conversational AI and advanced supply chain tools to give sponsors greater control over complex global trials.

A family's personal journey with a rare disorder sparks a major investment in Quiver Bioscience's AI-powered therapy, aiming to treat Dup15q syndrome.

A landmark study reveals 100% tumor control with a personalized radiation therapy, offering profound new hope for patients with inoperable liver cancer.

As women in midlife turn to drugs like Ozempic, a new crisis is emerging: significant muscle loss. A new approach aims to protect metabolic health.

With promising Phase 2 data for its novel peptide therapies, Sapience Therapeutics is engaging investors, signaling a critical push for future growth.

New data shows Imofinostat turns 'cold' colorectal tumors 'hot' for immunotherapy and breaks chemo-resistance in pancreatic cancer, fueling pivotal trials.

IVY Rx unveils its 2026 compounded GLP-1 program with clear pricing, but operates in a market facing intense FDA warnings and regulatory uncertainty.

A jury found Abbott's Similac caused a fatal gut disease in premature infants, igniting a legal firestorm over what the formula giant knew and when.

A Chicago jury found Abbott liable for infants' injuries from Similac, adding to a wave of lawsuits over the deadly intestinal disease NEC.

European digital health firm Apomeds launches in the UK, targeting the booming telehealth market with a focus on discreet, high-demand treatments.

Lupin has launched a generic version of the blockbuster diabetes drug Farxiga, signaling lower costs for patients and a major shake-up in the SGLT2 market.

A new collaboration between Emporia Research and Definitive Healthcare promises unprecedented accuracy in recruiting healthcare decision-makers for vital research.

With a massive $54M Series A, Vivatides Therapeutics aims to solve RNA's biggest delivery problem, unlocking new treatments for a host of chronic diseases.

Jetstream Venture Fund's deals with Surf Therapeutics and Hill Research signal a new era of accessible venture capital backing transformative technologies.